'The Global Market for Needle-Free Injection Devices Will be Worth $4.49bn by 2022' Predicts visiongain Research

LONDON, September 14, 2012 /PRNewswire/ --

A new report by visiongain, a London-based business information provider, predicts that the global market for Needle-Free Injection Devices will be worth $4.49bn by 2022. The market generated sales of $1.09bn in 2011.

The delivery of medicine and drugs to patients is typically though the use of pills, tablets or even in liquid form. In some cases when the drug needs to reach the systemic circulation quicker, or when the drug has a shorter half life, often seen during emergencies, the drug will be administered by injection, for example, intravenously (i.v.). Indeed, there are large numbers of therapies, particularly protein-, gene- and vaccine-based medications that cannot be delivered orally. In recent years however, there has been growing concern over the use of needle-based injections. Much of this concern is psychologically-based where patients suffer from a phobia of needles. This has been particularly documented across large demographic groups, such as diabetics. One such alternative, which is growing in popularity and has received considerable attention during the past few years (especially as the safety and efficacy of needle/syringe delivery has been questioned) is Needle-Free Injection (NFI) technology.

Visiongain's healthcare industry analyst, says "While drug pills and tablets have been the most widely accepted form of drug delivery, in recent years there has been a shift away from these traditional methods and towards specialised delivery systems that can provide safer and more effective methods of medication. A needle free injection device is one example of an innovative system that has addressed patient concerns regarding the risk of needle infections, frequency of injections and painful drug administration. Due to high start up and maintenance costs, the initial adoption of needle-free systems was slow. However, with the introduction of devices that are now designed to work with existing drug formulations, development costs have been reduced. This has accelerated the adoption of needle-free injection devices, indicated for a wide variety of administrations including vaccines, hormones and anaesthetics".

Visiongain's report; Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022,  also suggests that the world needle free injection device market will also benefit from a large number of leading drugs losing patent, which offers opportunity for companies in the needle-free delivery market to develop novel devices for their delivery. This helps pharmaceutical companies manage the life cycle of their drugs and allows for patent extensions.

Visiongain predicts that this market will grow steadily to 2022. The future of needle free injection systems appears promising and has significant potential for growth owing to the increasing demand for safer, less painful methods of drug administration. This new report adds to visiongain's wide range of analytical reports in healthcare and other industry areas.

For further information concerning the Visiongain's Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022 please visit http://www.visiongain.com/Report/893/Medical-Device-Leader-Series-Top-Needle-Free-Injection-Device-Manufacturers-2012-2022 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

Companies Listed in the report include:

Activa (Advantajet)
Akra Dermojet
Antares Pharma
Astellas Pharma
AstraZeneca
Battelle
Bioject Medical Technologies
BioValve Technologies
Bristol-Myers Squibb
Covidien
Crossject Medical technology
D'Antonio Consultants International
Diabetes Management International
Dr. Reddy's Laboratories
Durect
Echo Therapeutics
Eli Lilly & Co
Eurojet Medical
Ferndale Pharma Group
Ferring Pharmaceuticals
Glide Pharma
GlaxoSmithKline (GSK)
JCR Pharmaceuticals
Mallinckrodt
Medical International Technologies
Merck Serono
MGlas AG
Minnesota Rubber and Plastics (MRP)
MPI Research
National Medical Products
Nektar Therapeutics
Nova Nordisk
Novartis
Nypro Limited
Patheon
Penjet Corporation
Pfizer
PharmaJet
Sanofi-Pasteur
Takeda
Teva Pharmaceuticals
Valeritas
Zogenix

Government Agencies and Other Organisations Mentioned in This Report
FDA
WHO
UN
CDRH
EU
USAMRIID
PATH
CDC 

Contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com 
Tel: +44-(0)20-7336-6100